Expert Video Report on Immunotherapy for Colorectal Carcinoma

ESMO 2018 Congress

Speaker: Konstantinos Kamposioras

Commenting on the findings from CheckMate142, MODUL and NICHE studies presented at ESMO 2018 Congress, Dr Konstantinos Kamposioras says that very interesting results were presented on immunotherapy in colorectal cancer in both primary treatment and neoadjuvant settings. Results for first-line immunotherapy combination in MSI-high patients are positive both for progression-free and overall survival, but the results from immunotherapy after induction chemotherapy in BRAFwt metastatic CRC patients are inconclusive.
He concludes that practice is changing and immunotherapy is approaching the first-line treatment. However, further studies are needed to confirm the outcomes reported at ESMO 2018 Congress in Munich. The results in the neoadjuvant setting are promising and potentially practice changing in terms of further improvement of survival in CRC patients.

ESMO 2018 Congress abstracts: